Comparative Pharmacology
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus QUINACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus QUINACT.
DISOPYRAMIDE PHOSPHATE vs QUINACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 mL/min), requiring dose adjustment.
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category D/X
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)